86 related articles for article (PubMed ID: 18069262)
21. In vivo models of multiple myeloma (MM).
Sanchez E; Chen H; Berenson JR
Biochem Pharmacol; 2014 Jun; 89(3):313-20. PubMed ID: 24704250
[TBL] [Abstract][Full Text] [Related]
22. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma.
Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S
Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
Huang YW; Richardson JA; Vitetta ES
Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632
[TBL] [Abstract][Full Text] [Related]
24. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
Mitsiades CS; Mitsiades NS; Bronson RT; Chauhan D; Munshi N; Treon SP; Maxwell CA; Pilarski L; Hideshima T; Hoffman RM; Anderson KC
Cancer Res; 2003 Oct; 63(20):6689-96. PubMed ID: 14583463
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma.
Kikuchi Y; Uno S; Kinoshita Y; Yoshimura Y; Iida S; Wakahara Y; Tsuchiya M; Yamada-Okabe H; Fukushima N
Leuk Res; 2005 Apr; 29(4):445-50. PubMed ID: 15725479
[TBL] [Abstract][Full Text] [Related]
28. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
29. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Biochem Biophys Res Commun; 2004 Apr; 316(3):859-66. PubMed ID: 15033480
[TBL] [Abstract][Full Text] [Related]
30. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.
Pattengale PK
Am J Pathol; 1997 Sep; 151(3):647-9. PubMed ID: 9284811
[No Abstract] [Full Text] [Related]
31. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
[TBL] [Abstract][Full Text] [Related]
32. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen.
Ujiie H; Shibaki A; Nishie W; Sawamura D; Wang G; Tateishi Y; Li Q; Moriuchi R; Qiao H; Nakamura H; Akiyama M; Shimizu H
J Immunol; 2010 Feb; 184(4):2166-74. PubMed ID: 20089696
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP
Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234
[TBL] [Abstract][Full Text] [Related]
34. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
Bueno C; Lopes LF; Greaves M; Menendez P
Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
[No Abstract] [Full Text] [Related]
35. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin enhances immune responses in mice.
Katz O; Gil L; Lifshitz L; Prutchi-Sagiv S; Gassmann M; Mittelman M; Neumann D
Eur J Immunol; 2007 Jun; 37(6):1584-93. PubMed ID: 17458859
[TBL] [Abstract][Full Text] [Related]
37. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
38. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
39. Animal model of human disease. Multiple myeloma.
Radl J; Croese JW; Zurcher C; Van den Enden-Vieveen MH; de Leeuw AM
Am J Pathol; 1988 Sep; 132(3):593-7. PubMed ID: 3414786
[No Abstract] [Full Text] [Related]
40. BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.
Hamouda MA; Jacquel A; Robert G; Puissant A; Richez V; Cassel R; Fenouille N; Roulland S; Gilleron J; Griessinger E; Dubois A; Bailly-Maitre B; Goncalves D; Mallavialle A; Colosetti P; Marchetti S; Amiot M; Gomez-Bougie P; Rochet N; Deckert M; Avet-Loiseau H; Hofman P; Karsenti JM; Jeandel PY; Blin-Wakkach C; Nadel B; Cluzeau T; Anderson KC; Fuzibet JG; Auberger P; Luciano F
J Exp Med; 2016 Aug; 213(9):1705-22. PubMed ID: 27455953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
